Slide(US) | $25,000,000 | (Jun 17, 2025)
Lumion (Formerly Mia Share) | $10,700,000 | (Jun 17, 2025)
Warp(US) | $10,000,000 | (Jun 17, 2025) Certified by Founder
Lodge
eGenesis, Inc.
start up
United States
- Cambridge, MA
- 04/09/2024
- Series B
- $191,000,000
eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis’ mission is to solve the global organ shortage crisis by developing a scalable alternative to allotransplantation.
eGenesis is reinvigorating the field of xenotransplantation by addressing the key virology and immunology hurdles that have prevented its advancement to date, and is developing commercially-viable products to save and improve the lives of patients who are waiting for an organ transplant.
- Industry Biotechnology Research
- Website https://egenesisbio.com/
- LinkedIn https://www.linkedin.com/company/egenesisbio/
Yupp | $33,000,000 | (Jun 17, 2025)
PostHog | $70,000,000 | (Jun 17, 2025)
Ellipsis Health | $45,000,000 | (Jun 17, 2025)
Juniper Square | $130,000,000 | (Jun 17, 2025)
Cluely | $5,300,000 | (Jun 17, 2025)
OneBalance | $20,000,000 | (Jun 13, 2025)